Back to Search Start Over

Wearable, noninvasive, pulsed shortwave (radiofrequency) therapy for analgesia and opioid sparing following outpatient surgery: A proof-of-concept case series.

Authors :
Ilfeld BM
Said ET
Gabriel RA
Curran BP
Swisher MW
Jacobsen GR
Wallace AM
Doucet J
Adams LM
Ventro GJ
Abdullah B
Finneran JJ 4th
Source :
Pain practice : the official journal of World Institute of Pain [Pain Pract] 2023 Jun; Vol. 23 (5), pp. 553-558. Date of Electronic Publication: 2022 Dec 13.
Publication Year :
2023

Abstract

Background: It is often difficult to concurrently provide adequate analgesia while minimizing opioid requirements following ambulatory surgery. Nonthermal, pulsed shortwave (radiofrequency) fields are a noninvasive treatment used as an adjunct analgesic and wound healing therapy. The devices may be placed by nursing staff in less than a minute, are relatively inexpensive and readily available, theoretically provide analgesia for nearly any anatomic location, and have no systemic side effects-patients cannot detect any sensations from the devices-or significant risks. Here we present a case series to demonstrate the use of pulsed, electromagnetic field devices for outpatient herniorrhaphy and breast surgery.<br />Case Report: Following moderately painful ambulatory umbilical (n = 3) and inguinal (n = 2) hernia repair as well as bilateral breast surgery (n = 2), patients had taped over their surgical incision(s) 1 or 2 noninvasive, wearable, disposable, pulsed shortwave therapy devices (RecoveryRx, BioElectronics Corporation, Frederick, Maryland) which functioned continuously for 30 days. Average resting pain scores measured on the 0-10 numeric rating scale were a median of 0 during the entire treatment period. Six patients avoided opioid use entirely, while the remaining individual required only 5 mg of oxycodone during the first postoperative day.<br />Conclusions: These cases demonstrate that the ambulatory use of pulsed shortwave devices is feasible and may be an effective analgesic, possibly obviating opioid requirements following outpatient herniorrhaphy and breast surgery. Considering the lack of any side effects, adverse events, and misuse/dependence/diversion potential, further study with a randomized, controlled trial appears warranted.<br /> (© 2022 World Institute of Pain.)

Details

Language :
English
ISSN :
1533-2500
Volume :
23
Issue :
5
Database :
MEDLINE
Journal :
Pain practice : the official journal of World Institute of Pain
Publication Type :
Report
Accession number :
36463434
Full Text :
https://doi.org/10.1111/papr.13188